|
 |
|
      |
|
|
|
 Research & Giving News Article  Animal studies show the protein could alleviate psychotic symptoms Neuropeptide S (NPS), so named by Rainer K. Reinscheid, Ph.D., a NARSAD 2004 Young Investigator and assistant professor in the program in pharmaceutical sciences at the University of California, Irvine, is produced by a small cluster of cells in the brainstem, yet its specialized receptors are found in several areas of the brain, including those that are associated with the regulation of arousal, sleep and wakefulness, anxiety, appetite, learning and memory. Dr. Reinscheid and his colleagues reported finding the new neuropeptide last year and described animal studies showing how binding of NPS to its receptors on the surfaces of neurons promotes strong arousal, suppresses all phases of sleep and lessens anxiety in stressful or unfamiliar situations. At ICN 2006, Dr. Reinscheid’s group reported how NPS also can reduce the biochemical and behavioral symptoms of schizophrenia in an established animal model for this mental illness that affects some 2 million Americans. Animals pretreated with NPS before receiving a drug that normally induces psychotic-like behaviors did not develop the signature behavioral symptoms and neurochemical features of schizophrenia, reported Naoe Okamura, M.D., Ph.D., who is a co-worker of Dr. Reinscheid at the University of California, Irvine. “Although preliminary, our animal studies indicate the NPS receptor should be explored as a target for the development of novel antipsychotic drugs,” Dr. Reinscheid said. “Whether molecules activating the NPS system will prove to be better drugs than others used to treat the symptoms of schizophrenia remains to be seen. We still have a very long way to go before proving it can alleviate symptoms in humans as we’ve seen it do in rodents.” “We’ve already seen how NPS is unique, being able to modulate both arousal and stress responses. So it could potentially be a target for drugs to treat anxiety and, interestingly, both insomnia and narcolepsy,” he added. The receptor for NPS belongs to a class of those with similar structure called G protein-coupled receptors. Collectively, they have a hand in modulating most every physiological process in the body and brain. Moreover, according to Dr. Reinscheid, about 40 percent of drugs on the market target the function and various actions of these receptors. Dr. Reinscheid’s lab is only beginning to understand how the NPS system works. Thus far, the team’s research suggests it acts much like an excitatory neurotransmitter that initiates an impulse by the receiving neuron. Currently, the team is looking at whether natural mutations in the genes of NPS and its receptor might be associated with mental disorders and developing animal models that lack parts of the NPS system in order to better understand its functions. Held in a different part of the world every four years under the auspices of the International Neuroendocrine Federation, this year’s congress – Bridging Neuroscience and Endocrinology – is being sponsored by the American Neuroendocrine Society and the University of Pittsburgh School of Medicine. The first full day of the program, June 20, was held in conjunction with the 10th Annual Meeting of the Society for Behavioral Neuroendocrinology. Permission was granted to NARSAD: The Mental Health Research Association to reprint this release by the University of Pittsburgh School of Medicine on behalf of the International Neuroendocrine Federation. |
Media Contact
Upcoming NARSAD Events
Latest News from NARSAD
Spotlight
|
|
For the Media